CHOP Treats 500th CAR T Patient
Published on

CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.
Published on
CHOP has treated its 500th patient with CAR T-cell immunotherapy, a “living drug” that harnesses the power of a patient’s own immune system to fight cancer.
Published on
Two researchers from Children’s Hospital of Philadelphia (CHOP) were recently selected by the health and science news outlet STAT as 2022 Wunderkinds, an award that celebrates the next generation of scientific superstars who are making significant contributions to biomedical research.
Published on
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Published on
Researchers from Children’s Hospital of Philadelphia (CHOP) have found that economically disadvantaged children treated with CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) fair just as well as children from more socioeconomically advantaged backgrounds.
Published on
CHOP researchers have identified a protein on the surface of multiple pediatric brain tumors that they can target using immunotherapy in preclinical models.
Published on
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
Published on
A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.
Published on
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Published on
International collaboration aims to ensure more equitable access to transformative personalized cancer therapy.
Published on
Whitehead received life-saving treatment at CHOP, under the care of Dr. Stephan Grupp, transforming the field of cancer immunotherapy.